US biotech firm Agensys has filed suit in California, accusing Suzhou Zelgen, Shanghai Zelgen, Gensun Biopharma, and Sheng of misappropriating its proprietary LRRC15 antibody technology to support a series of patent applications.

Read more | Read the complaint | Exhibit 1 | Exhibit 2